Nirsevimab (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Nirsevimab" in French language version.

refsWebsite

Global rank French rank

2nih.gov

4^th place

12^th place

2doi.org

2^nd place

3^rd place

2semanticscholar.org

11^th place

325^th place

1sanofi.com

low place

9,977^th place

1astrazeneca.com

low place

1nejm.org

2,374^th place

298^th place

1nasdaq.com

2,740^th place

5,605^th place

1clinicaltrials.gov

5,225^th place

6,624^th place

1fda.gov

447^th place

1,409^th place

1europa.eu

68^th place

67^th place

1lamontagne.fr

5,039^th place

299^th place

astrazeneca.com

« Nirsevimab MELODY Phase III trial met primary endpoint of reducing RSV lower respiratory tract infections in healthy infants », Online, AstraZeneca, 26 avril 2021 (consulté le 27 décembre 2021)

clinicaltrials.gov

https://www.clinicaltrials.gov/ct2/show/NCT02878330

doi.org

dx.doi.org

Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, Wählby Hamrén U, Mankad VS, Ren P, Takas T, Abram ME, Leach A, Griffin MP, Villafana T, « Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants », The New England Journal of Medicine, vol. 386, n^o 9,‎ mars 2022, p. 837–846 (PMID 35235726, DOI 10.1056/NEJMoa2110275, S2CID 247220023)
Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Simões EA, Esser MT, Khan AA, Dubovsky F, Villafana T, DeVincenzo JP, « Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants », The New England Journal of Medicine, vol. 383, n^o 5,‎ juillet 2020, p. 415–425 (PMID 32726528, DOI 10.1056/NEJMoa1913556, S2CID 220876651)

europa.eu

ema.europa.eu

European Medicines Agency, Beyfortus (nirsevimab), June 23, 2023

fda.gov

FDA approves new drug to prevent RSV in babies and toddlers. News release of the Food and Drug Administration, July 17, 2023

lamontagne.fr

« Épidémie de Bronchiolite chez les nourrissons : un traitement préventif, le nirsevimab, approuvé par l'UE », sur La Montagne, 4 novembre 2022 (consulté le 5 janvier 2023).

nasdaq.com

Zacks Equity Research, « Pfizer's (PFE) RSV Jab Gets Another Breakthrough Therapy Tag », sur Nasdaq, 25 mars 2022 (consulté le 8 avril 2022)

nejm.org

Muller WJ, Madhi SA, Seoane Nuñez B et al. Nirsevimab for prevention of RSV in term and late-preterm infants, N Engl J Med, 2023;388:1533-1534

nih.gov

ncbi.nlm.nih.gov

Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, Wählby Hamrén U, Mankad VS, Ren P, Takas T, Abram ME, Leach A, Griffin MP, Villafana T, « Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants », The New England Journal of Medicine, vol. 386, n^o 9,‎ mars 2022, p. 837–846 (PMID 35235726, DOI 10.1056/NEJMoa2110275, S2CID 247220023)
Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Simões EA, Esser MT, Khan AA, Dubovsky F, Villafana T, DeVincenzo JP, « Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants », The New England Journal of Medicine, vol. 383, n^o 5,‎ juillet 2020, p. 415–425 (PMID 32726528, DOI 10.1056/NEJMoa1913556, S2CID 220876651)

sanofi.com

« Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial », Online, Sanofi, 26 avril 2021 (consulté le 27 décembre 2021)

semanticscholar.org

api.semanticscholar.org

Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, Wählby Hamrén U, Mankad VS, Ren P, Takas T, Abram ME, Leach A, Griffin MP, Villafana T, « Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants », The New England Journal of Medicine, vol. 386, n^o 9,‎ mars 2022, p. 837–846 (PMID 35235726, DOI 10.1056/NEJMoa2110275, S2CID 247220023)
Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Simões EA, Esser MT, Khan AA, Dubovsky F, Villafana T, DeVincenzo JP, « Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants », The New England Journal of Medicine, vol. 383, n^o 5,‎ juillet 2020, p. 415–425 (PMID 32726528, DOI 10.1056/NEJMoa1913556, S2CID 220876651)